Skip to main content
SpringerLink
Log in

How Should We Move the Field of Chemopreventive Agent Development Forward in a Productive Manner?

  • Conference paper
Tumor Prevention and Genetics III

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 166))

Abstract

Epidemiologic observations and preclinical experimental investigations suggest that the prevention or reversal of precancers should be an effective strategy in humans to control cancer. Although “proof of principle” has been established in humans, the results of randomized trials have not been confirmatory in most cases. Toxicity in normal or near-normal populations has also been greater than anticipated. We examine the problems associated with testing chemoprevention agents in humans and offer a process and guidelines that may better inform the logical development of this relatively young clinical field.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alberts DS, Martinez ME, Roe DJ, et al (2000) Lack of effect of high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians’ Network. N Engl J Med 342:1156–1162

    Article  PubMed  CAS  Google Scholar 

  • Armstrong T, Taylor T, Meyskens FL Jr (2003) Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev 12:589–592

    PubMed  Google Scholar 

  • Baker SG (2000) Identifying combinations of cancer markers for further study as triggers of early intervention. Biometrics 56:1082–1087

    Article  PubMed  CAS  Google Scholar 

  • Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, McKeown-Eyssen G, Summers RW, Rothstein R, Burke CA, Snover DC, Church TR, Allen JI, Beach M, Beck GJ, Bond JH, Byers T, Greenberg ER, Mandel JS, Marcon N, Mott LA, Pearson L, Saibil F, van Stolk RU (2003) A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891–899

    Article  PubMed  CAS  Google Scholar 

  • Croghan MK, Aicken MG, Meyskens FL Jr (1991) Dose-related a-difluoromethylornithine (DFMO) ototoxicity (reversible hearing loss). Am J Clin Oncol 14:331–335

    PubMed  CAS  Google Scholar 

  • Fisher B, Costantino JP, Wickerham DL, Redmond CD, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

    Article  PubMed  CAS  Google Scholar 

  • Fleming TR, DeMets DL (1996) Surrogate end points in clinical trials: are we being misled? Ann Intern Med 125:605–613

    PubMed  CAS  Google Scholar 

  • Follen M, Meyskens FL Jr, Atkinson EN, Schottenfeld D (2001) Why most randomized phase II cervical cancer chemoprevention trials are uninformative: lessons for the future. J Natl Cancer Inst 93:1293–1296

    Article  PubMed  CAS  Google Scholar 

  • Goodman GE (1992) The clinical evaluation of cancer chemoprevention agents: defining and contrasting phase I, II, and III objectives. Cancer Res 52:2752s–2757s

    PubMed  CAS  Google Scholar 

  • Herrington DM, Howard TD (2003) Perspective: from presumed benefit to potential harm—hormone therapy and heart disease. N Engl J Med 349:519–545

    Article  PubMed  Google Scholar 

  • Hong WK, Lippman SM, Itri LM, et al (1990) Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 323:795–801

    Article  PubMed  CAS  Google Scholar 

  • Ioannidis JP, Haidich A, Pappa M, Kokovi S, Tektonida M, Contopoulos-Ioannidis D, Lau JP (2001) Comparison of evidence of treatment effects in randomized and non-randomized studies. J Am Med Assoc 286:821–830

    Article  CAS  Google Scholar 

  • Kelloff GJ, Johnson JR, Crowell JA, Boone CW, et al (1995) Approaches to the development and the marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4:1–10

    PubMed  CAS  Google Scholar 

  • Kelloff GJ, Sigman CC, Johnson KM, et al (2000) Perspective on surrogate end point in the development of drugs that reduce the risk of cancer. Cancer Epidemiol Biomarkers Prev 9:127–137

    PubMed  CAS  Google Scholar 

  • Lippman SM, Lee JJ, Karp DD, Vokes EE, Benner SE, Goodman GE, Khuri FR, Marks R, Winn RJ, Fry W, Graziano SL, Gandara DR, Okawara G, Woodhouse CL, Williams B, Perez C, Kim HW, Lotan R, Roth JA, Hong WK (2001) Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 93:605–618

    PubMed  CAS  Google Scholar 

  • Meyskens FL Jr (1992a) Biology and intervention of the premalignant process. Cancer Bull 43:475–480

    Google Scholar 

  • Meyskens FL Jr (1992b) Biomarkers intermediate endpoints and cancer prevention. J Natl Cancer Inst Monogr 13:177–182

    PubMed  Google Scholar 

  • Meyskens FL Jr (1998) Chemoprevention of cancer: a reasonable strategy? Recent Results Cancer Res 151:113–121

    Google Scholar 

  • Meyskens FL Jr (2000a) Cancer prevention in the Year 2025: an anticipation. Eur J Cancer 36:1737–1740

    Article  PubMed  Google Scholar 

  • Meyskens FL Jr (2000b) Cancer population genetics and tumour prevention: an unfulfilled paradigm. Eur J Cancer 36:1189–1192

    Article  PubMed  Google Scholar 

  • Meyskens FL Jr (2000c) Criteria for implementation of large and multiagent clinical chemoprevention trials. J Cell Biol 34:115–120

    Google Scholar 

  • Meyskens FL Jr (2001) Development of difluoromethylornithine and Bowman-Birk inhibitor as chemoprevention agents by assessment of relevant biomarker modulation: some lessons learned. In: Miller B, Bartsch H, Buffeta P, Dragsted L, Varinco H (eds) Biomarkers in Cancer Prevention. IARC Publications, Lyon, pp 49–56

    Google Scholar 

  • Meyskens FL Jr, Gerner EW (1999) Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5:945–951

    PubMed  CAS  Google Scholar 

  • Meyskens FL Jr, Emerson SS, Pelot D, et al (1994) Dose de-escalation chemoprevention trial of a-difluoromethylornithine in patients with colon polyps. J Natl Cancer Inst 86:1122–1130

    PubMed  Google Scholar 

  • Meyskens FL Jr, Gerner E, Emerson S, Pelot D, et al (1998) Effect of α difluoromethylornithine on rectal mucosal levels for polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 90:1212–1218

    Article  PubMed  CAS  Google Scholar 

  • Meyskens FL Jr, Doyle KJ, McLaren CE, Shanks JE (2001) Effects of difluoromethylornithine chemoprevention on audiometry thresholds and otoacoustic emissions. Arch Otolaryngol Head Neck Surg 127:553–558

    PubMed  Google Scholar 

  • Omenn GS, Goodman GE, Thronquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, et al (1996) Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150–1155

    Article  PubMed  CAS  Google Scholar 

  • Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, Petrelli N, Pipas JM, Karp DD, Loprinzi CL, Steinbach G, Schilsky R (2003) A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 348:883–890

    PubMed  CAS  Google Scholar 

  • Schatzkin A, Lanza E, Corle D, et al (2000) Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study. N Engl J Med 342:1149–1155

    Article  PubMed  CAS  Google Scholar 

  • Sporn MB, Dunlop NM, Newton DL, Smith JM (1976) Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 35:1332–1338

    PubMed  CAS  Google Scholar 

  • Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr (2003) The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215–224

    Article  PubMed  CAS  Google Scholar 

  • Viner JL, Umar A, Hawk ET (2002) Chemoprevention of colorectal cancer: problems, progress, and prospects. Gastroenterol Clin North Am 3:971–999

    Google Scholar 

  • Wang KK, Kim JY (2003) Photodynamic therapy in Barrett’s esophagus. Gastrointest Endosc Clin N Am 13:483–489

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine (Hematology/Oncology) and Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, CA, 92868, USA

    Frank Louis Meyskens

  2. Division of Cancer Prevention, National Cancer Institute, Bethesda, MD, USA

    Eva Szabo

Authors
  1. Frank Louis Meyskens
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eva Szabo
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Zentrum für Tumordiagnostik und Prävention, Rorschacherstrasse 150, 9006, St. Gallen, Switzerland

    Hans-Jörg Senn  & Rudolf Morant  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Meyskens, F.L., Szabo, E. (2005). How Should We Move the Field of Chemopreventive Agent Development Forward in a Productive Manner?. In: Senn, HJ., Morant, R. (eds) Tumor Prevention and Genetics III. Recent Results in Cancer Research, vol 166. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-26980-0_9

Download citation

  • DOI: https://doi.org/10.1007/3-540-26980-0_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-22228-6

  • Online ISBN: 978-3-540-26980-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation